RXRX
Recursion Pharmaceuticals, Inc.
There isn't enough reported data to score RXRX yet.
RXRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
RXRX's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
RXRX PE Valuation
RXRX has no meaningful PE right now: it lost money over the past year.
RXRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect RXRX's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
RXRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.86 | +$0.97 |
| Q2 2026 | -$1.00 | +$0.81 |
| Q1 2026 | -$1.16 | +$0.64 |
| Q4 2025 | -$1.44 | +$0.25 |
| Q3 2025 | -$1.83 | -$0.27 |
| Q2 2025 | -$1.81 | -$0.16 |
| Q1 2025 | -$1.80 | -$0.17 |
| Q4 2024 | -$1.69 | -$0.11 |
RXRX is still losing money, but far less than before: $0.86 per share over the past year, against $2.07 at its worst in late 2021.
RXRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.6M | +258% |
| Q2 2026 | $7.7M | -60% |
| Q1 2026 | $6.5M | -56% |
| Q4 2025 | $35.5M | +682% |
| Q3 2025 | $5.2M | -80% |
| Q2 2025 | $19.2M | +33% |
| Q1 2025 | $14.7M | +6.9% |
| Q4 2024 | $4.5M | -58% |
RXRX's revenue is growing: $19M last quarter, up 258% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -664% | +2664 points |
| Q2 2026 | -1760% | -843 points |
| Q1 2026 | -1986% | -688 points |
| Q4 2025 | -305% | +3738 points |
| Q3 2025 | -3328% | -2951 points |
| Q2 2025 | -917% | -219 points |
| Q1 2025 | -1298% | -599 points |
| Q4 2024 | -4042% | -3134 points |
RXRX's operating margin was −664% last quarter, up 2664 points from the same quarter a year ago.
RXRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$77.8M | +$39.8M |
| Q2 2026 | -$106M | -$26.4M |
| Q1 2026 | -$81.4M | +$52.4M |
| Q4 2025 | -$47.3M | +$69.4M |
| Q3 2025 | -$117.6M | -$53.8M |
| Q2 2025 | -$79.6M | +$3.8M |
| Q1 2025 | -$133.8M | -$24.8M |
| Q4 2024 | -$116.7M | -$40.6M |
RXRX has burned cash in almost every quarter: −$312M over the past year, against −$448M the year before.
RXRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2% | +10.5M shares |
| 1 year | +21% | +96M shares |
| 3 years | +170% | +342M shares |
| 5 years | +2257% | +520M shares |
| Available history | +223% | +375M shares |
RXRX has 543M diluted shares, up 21% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RXRX Net Leverage
RXRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RXRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.7 | Neutral |
| Stochastic | 31.6 | Neutral |
RXRX's weekly RSI is 47 (neutral) and its Stochastic is 32 (neutral).
RXRX PE vs Healthcare Sector
RXRX has no meaningful PE right now: it lost money over the past year.
RXRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.78 | 12% below |
| 20 week MA | $3.52 | 5.4% below |
| 50 week MA | $3.62 | 8% below |
| 100 week MA | $4.69 | 29% below |
| 200 week MA | $6.45 | 48% below |
RXRX is in a downtrend: it's below all five of its weekly moving averages, and 48% below its 200-week average.
RXRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.3 | $16.8 | -46% |
| 2022 | $16.8 | $7.51 | -55% |
| 2023 | $7.51 | $9.86 | +31% |
| 2024 | $9.86 | $7.39 | -25% |
| 2025 | $7.39 | $4.25 | -42% |
| 2026 YTD | $4.25 | $3.33 | -22% |
RXRX has finished lower in four of the last five years. It's down 22% so far in 2026.